WCLC Sept 2021 | DESTINY-Lung01: a practice-changing trial for NSCLC

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, shares his thoughts on the practice-changing DESTINY-Lung01 trial (NCT03505710) that demonstrated the efficacy of trastuzumab deruxtecan (T-DXd) for patients with HER2-mutant non-small cell lung cancer (NSCLC). Dr Spira underlines the importance of testing patients for this mutation to enable access to this highly promising targeted therapy. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.